Bivalent human hookworm vaccine - SabinAlternative Names: Na-APR-1 (M74)/Alhydrogel® and Na-GST-1/Alhydrogel® bivalent hookworm vaccine
Latest Information Update: 06 Feb 2017
At a glance
- Originator Sabin Vaccine Institute
- Developer Johns Hopkins University; Sabin Vaccine Institute; The George Washington University of Washington, D.C.; University of California at San Francisco
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hookworm infections